BioSpace News Archive

A new randomized controlled clinical study finds that Hinge Health’s Enso delivers 2x more pain reduction and improves mobility 3x compared to a control device.

Cyclo Therapeutics, Inc. today announced that N. Scott Fine, Chief Executive Officer and Lise Lund Kjems, MD, PhD, Chief Medical Officer of Cyclo Therapeutics will participate in the Virtual Investor Roundtable Event on Tuesday, November 16, 2021 at 11:00 AM ET.

Pipeline Therapeutics today announced that the company will participate in two upcoming investor conferences.

Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”) a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage, diagnosis and monitoring of disease progression, today announced the pricing of an underwritten Initial Public Offering of 2,160,000 units.

Aphios Corporation today announced that it has been granted Chinese Patent No. 201811111996.8 by China National Intellectual Property Administration on October 26, 2021.

VectivBio Holding AG today provided a business update for the third quarter ended September 30, 2021.

AmerisourceBergen today announced that it is now offering Prime Therapeutics’ IntegratedRx™ – Oncology program to eligible hospital, health system and independent oncology practice customers.

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the “Company” or “Inspira Technologies”), announced today it has filed a Patent Cooperation Treaty (PCT) patent application for its novel dual lumen cannula, accompanying an extracorporeal respiratory life support/saving system aimed at rebalancing patient’s oxygen saturation and carbon dioxide levels.

Viome Life Sciences, a mission-driven systems biology company aiming to help individuals improve their health, today announces its raise of $54M in a pre-series C convertible funding with participation from existing investors and new investors.

Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or the “Company”), is pleased to announce that it has completed recruitment for the initial dosimetry phase of its US-based SECuRE clinical trial (NCT04868604)[1] investigating SAR-bisPSMA Targeted Copper Theranostics (TCT) in patients with metastatic castrate-resistant prostate cancer (mCRPC).